EZH2 Inhibitor Crystal Form for Stable Cancer Therapy Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with EZH2, such as cancer, lack effective small molecule inhibitors that can target this enzyme effectively.
Innovation Solution
Development of crystalline forms of the small molecule inhibitor, 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, which provide enhanced therapeutic potential by inhibiting EZH2 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule inhibitors are developed to target EZH2 enzyme, then therapeutic potential for treating cancer and other proliferative disorders is improved, but the lack of effective inhibitors with appropriate pharmacological properties represents a technical barrier
Solution Approach 1:
The patent applies parameter changes by developing multiple crystalline forms (polymorphs) of the EZH2 inhibitor compound. Each crystalline form has distinct physical properties including different melting points, solubilities, and stability characteristics. This allows optimization of pharmacological properties such as bioavailability, half-life, and tissue distribution while maintaining the core inhibitory activity against EZH2 enzyme.
Solution Approach 2:
The patent creates composite material systems by formulating the EZH2 inhibitor in various crystalline forms with specific excipients and carriers. These composite pharmaceutical compositions are designed to enhance solubility, stabilize the active ingredient, and improve overall therapeutic performance. The different crystalline forms serve as distinct material states within the composite formulation system.
2Stability of the object's composition
If crystalline forms of the inhibitor are developed with defined X-ray powder diffraction patterns and thermal properties, then stability and efficacy are improved, but the complexity of characterizing and manufacturing specific crystalline forms increases
Solution Approach 1:
The patent applies preliminary action by pre-characterizing each crystalline form with comprehensive analytical methods including X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), and thermogravimetric analysis (TGA). This upfront characterization establishes fingerprint patterns for each polymorph, enabling quality control and batch consistency without requiring complex real-time analysis during manufacturing. The preliminary data serves as reference standards for routine quality assurance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline forms of the inhibitor demonstrate improved efficacy in treating conditions responsive to EZH2 inhibition, including various cancers, by providing specific and stable forms with defined X-ray powder diffraction patterns and thermal properties.
Implementation Method 1
crystalline Form 1 is characterized by an X-ray powder diffraction pattern having peaks at the following 2-theta angles: 10.0°, 13.3°, 14.9°, 20.2°, 20.8°, 22.2°, and 22.5°
Implementation Method 2
crystalline Form 1 is characterized by a differential scanning calorimetry thermogram having an endotherm at 179.5° C. (onset temperature)
Data Source
AI summary
The present disclosure relates to a crystalline Form 1 of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-di-methyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, which is useful as modulators the activity of histone methyl modifying enzymes. The present disclosure also provides pharmaceutically acceptable compositions comprising the crystalline form and methods of using said compositions in the treatment of various disorders.